Class summary at a glance.

Every drug in the Sphingosine 1-phosphate Receptor Modulator class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $278.9Mcombined across class
Total Rx claims: 59K10K unique beneficiaries
Generic mfrs (active): 15across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Fingolimod

Brand: Fingolimod · 48K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 2010-09-21

14 generic mfrs 259 plans require PA

Low NADAC$4.79

→

Avg plan cost$4.79

Part D spend $155.1M 1× spread, current vs floor

Class share

56%

of class CY24 spend

View profile →

Siponimod

Brand: MAYZENT · 10K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2019-03-26

1 generic mfrs 444 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $114.1M

Class share

41%

of class CY24 spend

View profile →

Ponesimod

Brand: PONVORY · 826 Part D claims (CY24) · 147 beneficiaries · First FDA approval: 2021-03-18

Brand-only (no generics) 24 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $9.6M

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.